Cleared Traditional

K791605 - GOAT ANTI-HUMAN ALPHA-1-ANTITRYPSIN

K791605 is the FDA 510(k) clearance for GOAT ANTI-HUMAN ALPHA-1-ANTITRYPSIN by Protos Laboratories. It is a Class 2 Immunology device (product code DEM) cleared through the Traditional 510(k) pathway after a 15-day FDA review.

K791605 · Protos Laboratories · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1979
Decision
15d
Days
Class 2
Risk

K791605 is an FDA 510(k) clearance for the GOAT ANTI-HUMAN ALPHA-1-ANTITRYPSIN. Classified as Alpha-1-antitrypsin, Antigen, Antiserum, Control (product code DEM), Class II - Special Controls.

Submitted by Protos Laboratories (Mchenry, US). The FDA issued a Cleared decision on September 4, 1979 after a review of 15 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5130 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Protos Laboratories devices

Submission Details

510(k) Number K791605 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 20, 1979
Decision Date September 04, 1979
Days to Decision 15 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
89d faster than avg
Panel avg: 104d · This submission: 15d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DEM Alpha-1-antitrypsin, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5130
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DEM Alpha-1-antitrypsin, Antigen, Antiserum, Control

All 23
Devices cleared under the same product code (DEM) and FDA review panel - the closest regulatory comparables to K791605.
QM300 ALPHA1-ANTITRYPSIN ANTIBODY PACK
K875281 · Kallestad Diag, A Div. of Erbamont, Inc. · Feb 1988
QM2/QM300 CONTROL B PACK
K875283 · Kallestad Diag, A Div. of Erbamont, Inc. · Feb 1988
J.T. BAKER ALPHA-1-ANTITRYPSIN NEPHELO
K801669 · J.T. Baker Chemical Co. · Sep 1980
RID SYSTEM-(ACP) TEST
K781408 · Icl Scientific · Aug 1978
LAS-R HUMAN ALPHA, ANTITRYPSIN TEST
K760916 · Hyland Therapeutic Div., Travenol Laboratories · Nov 1976